SCHEDULE: Blue Owl Capital Holdings LP Discloses Aktis Oncology Stake

Blue Owl Capital Holdings LP has filed a Schedule 13G, reporting beneficial ownership of 5.92% of Aktis Oncology, Inc. common stock as of March 31, 2026.

Summary

• Blue Owl Capital Holdings LP has filed a Schedule 13G, indicating it beneficially owns 3,161,348 shares of Aktis Oncology, Inc. common stock.
• This ownership stake represents 5.92% of the company's outstanding common stock.
• The filing is dated March 31, 2026, and the ownership information is based on 53,403,173 shares outstanding as of March 10, 2026, as reported in Aktis Oncology's 10-K.
• Blue Owl Capital Holdings LP is organized in Delaware and its principal business office is located at 399 Park Avenue, New York, New York 10022.
• The filing certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing control of the issuer.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it is a standard disclosure of beneficial ownership without additional commentary on the company's performance or future prospects.

Positives

• Blue Owl Capital Holdings LP's investment indicates confidence in Aktis Oncology, Inc.
• The disclosure of a significant stake (5.92%) can attract further investor interest.

Risks

• The filing does not detail the specific reasons for the investment or any strategic intentions beyond ordinary course of business.
• Potential for future changes in ownership or strategic actions by Blue Owl Capital Holdings LP could impact Aktis Oncology's stock.

Future Outlook

The filing does not contain forward-looking statements or guidance from Aktis Oncology, Inc. It is a disclosure of beneficial ownership by Blue Owl Capital Holdings LP.

Management Comments

• Blue Owl Capital Holdings LP certifies that the securities were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors accumulating significant stakes in publicly traded companies. This filing indicates Blue Owl Capital Holdings LP's interest in Aktis Oncology, Inc., a biotechnology company, which is a sector often subject to substantial institutional investment.

Stakeholder Impact

• Shareholders: The filing may signal increased institutional interest in Aktis Oncology, potentially influencing stock price and liquidity.
• Management: The company's management will be aware of Blue Owl Capital Holdings LP's significant stake, which could influence future strategic decisions or board composition discussions.

Key Dates

Keywords

Schedule 13G, Aktis Oncology, Blue Owl Capital Holdings LP, Beneficial Ownership, Common Stock, SEC Filing, Investment